32 stories mentioning RVMDUpdated 2d ago
Every FINWIRES story that references RVMD, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Lorence H. Kim, Director, on September 08, 2026, sold 17,090 shares in Revolution Medicines (RVMD) for $3,585,837. Following the Form 4 filing with the SEC, Kim has control over a total of 1,191 common shares of the company, with 1,191 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1628171/000119312526388156/xslF345X05/ownership.xml
Revolution Medicines (RVMD) could see strong long-term growth from Rasonque sales, expansion into earlier treatment, and new drugs and combination therapies pending upcoming trial results, Morgan Stanley said in a note Thursday.Morgan Stanley models about $12 billion in peak risk-adjusted sales across the company's drug portfolio by 2036, with potential sales of about $18 billion before adjusting for development risks, according to the note.The analysts see Rasonque as the company's main commercial base, while zoldonrasib, elironrasib and earlier-stage drugs could provide additional sources of growth and reduce reliance on one treatment, while combination treatments could become an important long-term driver by helping the company reach patients earlier in treatment and expand into more cancer types.The next 12 to 18 months will include the US launch of Rasonque, updates in colorectal cancer, progress from early-stage drugs and several late-stage studies, though weaker drug uptake or disappointing trial results remain key risks, the investment firm said.Morgan Stanley started coverage of Revolution Medicines with an overweight rating and a $255 price target.Price: $204.04, Change: $-3.64, Percent Change: -1.75%
(Updated to include price target in headline.)Revolution Medicines (RVMD) has an average rating of buy and mean price target of $242.68, according to analysts polled by FactSet.
Revolution Medicines (RVMD) has an average rating of buy and mean price target of $242.68, according to analysts polled by FactSet.
Revolution Medicines (RVMD) should post "strong launch numbers" for pancreatic cancer drug Rasonque (daraxonrasib), which would serve as a key driver of its 2026 and 2027 revenue, UBS Securities said in a Thursday note.The US Food and Drug Administration approved Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma, with the company to price the therapy at $39,800 for a 30-day supply.Street consensus for the company's 2026 and 2027 revenue already increased following the approval, but the updated projections remain achievable, UBS said. Revolution Medicines already had 2,000 patients on its expanded access program as of Q2, the brokerage noted.The consensus is for $152 million revenue in 2026 and $1.10 billion in 2027, while UBS estimates $193 million in 2026 and $1.91 billion in 2027, according to the note.UBS also noted the upcoming phase 3 data on daraxonrasib in non-small cell lung cancer by year-end 2027 as Revolution Medicines' next major clinical catalyst.UBS raised its price target on Revolution Medicines to $265 from $220, with a buy rating.Price: $206.08, Change: $-15.07, Percent Change: -6.81%
Revolution Medicines (RVMD) receiving a broader-than-expected Food and Drug Administration label for Rasonque strengthens its commercial outlook, Oppenheimer said.Management emphasized that the label does not set specific eligibility criteria, giving doctors and patients flexibility in treatment decisions, the analysts said in a note Wednesday, adding that this could allow Rasonque to be used in the first line before ongoing registrational studies are completed.Management said the company is well prepared for the commercial launch, with supply, distribution, sales teams, patient services, and reimbursement support all operational from day one.The company set a wholesale acquisition cost of $39,800 per 30-day supply. More than 2,000 patients have received Rasonque through preapproval access programs. Oppenheimer said it should support a smoother launch and greater physician familiarity with the drug."Rasonque's label flexibility, unprecedented survival benefit, compelling patient-reported outcomes, and launch readiness meaningfully increase the probability of commercial success," the analysts added.Oppenheimer raised its price target on Revolution Medicines to $260 from $230, with an outperform rating.Price: $220.36, Change: $+4.92, Percent Change: +2.28%
Revolution Medicines' (RVMD) Rasonque tablets for the treatment of metastatic pancreatic cancer could see a "rapid launch," driven by patient and physician interest amid a lack of alternative therapies, RBC Capital Markets said in a Wednesday note.The drug's pricing of $39,800 for a 30-day supply was above RBC's expectations, while payer friction is expected to be minimal, the brokerage said. RBC also expects Rasonque's "aggressive" adoption given its positive data and high awareness among doctors and patients, among others.RBC projects strong Rasonque revenue in Q3 and Q4, estimating $249 million in US sales in 2026, according to the note.The investment firm also said the drug's label language could provide flexibility for some patients to receive Rasonque in the frontline setting, despite the lack of a formal first-line approval.RBC raised its price target on Revolution Medicines to $251 from $203, with an outperform rating.Price: $218.34, Change: $+2.90, Percent Change: +1.35%
Revolution Medicines (RVMD) is expected to implement a rapid launch of its Rasonque therapy for metastatic pancreatic adenocarcinoma following US Food and Drug Administration approval, Wedbush Securities said in a note Thursday.In an investor call, analysts said the company noted that about 60% of patients are currently treated in community healthcare practices and the rest in the academic setting, with substantial efforts underway to educate potential prescribers.The brokerage said it expects Revolution Medicines to post 2027 revenue of $1.34 billion, compared with FactSet consensus of $1.03 billion, with about 2,000 patients treated under the expanded access program as of early August transitioning to commercial supply over the next two months.Wedbush retained an outperform rating on the stock and increased its price target to $225 from $201.Price: $218.28, Change: $+2.84, Percent Change: +1.32%
Revolution Medicines (RVMD) has an average rating of buy and mean price target of $235.82, according to analysts polled by FactSet.
Healthcare stocks fell late Wednesday afternoon, with the NYSE Healthcare Index shedding 1% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.9%.The iShares Biotechnology ETF (IBB) decreased 0.5%.In sector news, the Trump Administration is planning to announce a new round of drug-pricing agreements on Monday with several midsized biotech companies that would offer discounts to state Medicaid programs, Bloomberg reported. The companies would provide discounts so prices align with those charged in foreign markets and would be exempt from Medicare pilot programs requiring similar reductions, while tariff relief is part of some of the discussions, the report said.In corporate news, Eli Lilly (LLY) said Wednesday that a real-world study showed sustained use of its weight-management drug Zepbound was associated with lower healthcare costs among adults older than 55 with overweight or obesity, compared with similar untreated adults. Lilly shares were down 3.3%.Boston Scientific (BSX) is recalling thousands of its percutaneous catheters due to possible arterial sheath tip separation that could lead to complications with a retained tip, the US Food and Drug Administration confirmed in a Wednesday statement. Separately, Boston Scientific has identified a cybersecurity incident that affected some of its IT systems and led to global disruptions in operations, the company said Wednesday in a regulatory filing. Boston Scientific shares fell 3%.Revolution Medicines' (RVMD) Rasonque, or daraxonrasib, has been approved to treat metastatic pancreatic cancer, the US Food and Drug Administration said Wednesday. Revolution shares rose 0.4%.Biuohaven (BHVN) shares surged past 19% in Wednesday trading after the company signed a licensing and collaboration deal with SK Biopharmaceuticals for an investigational focal epilepsy treatment.
Revolution Medicines' (RVMD) once-daily oral Rasonque tablets for the treatment of metastatic pancreatic cancer are available in the US at a price of $39,800 for a 30-day supply, the company said Wednesday in a regulatory filing.The US Food and Drug Administration approved Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.Price: $215.95, Change: $+4.57, Percent Change: +2.16%
Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports
Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index falling 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.8%.The iShares Biotechnology ETF (IBB) decreased 0.3%.In corporate news, Boston Scientific (BSX) is recalling thousands of its percutaneous catheters due to possible arterial sheath tip separation that could lead to complications with a retained tip, the US Food and Drug Administration confirmed in a Wednesday statement. Separately, Boston Scientific has identified a cybersecurity incident that affected some of its IT systems and led to global disruptions in operations, the company said Wednesday in a regulatory filing. Boston Scientific shares were down 3.3%.Revolution Medicines' (RVMD) Rasonque, or daraxonrasib, has been approved for the treatment of metastatic pancreatic cancer, the US Food and Drug Administration said Wednesday. Revolution shares rose 2.9%.Summit Therapeutics (SMMT) partner Akeso reported "positive" results from a phase 3 trial of ivonescimab plus chemotherapy, compared with durvalumab plus chemotherapy as a first-line treatment of advanced biliary tract cancer. Summit shares jumped past 8%.
Revolution Medicines' (RVMD) Rasonque (daraxonrasib) has been approved for the treatment of metastatic pancreatic cancer, the US Food and Drug Administration said Wednesday.The approval is for treatment of adults with metastatic pancreatic adenocarcinoma, who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy, the FDA said.The most common side effects of the drug are rash, diarrhea, stomatitis, nausea, fatigue, among others, according to a statement.Price: $211.82, Change: $+0.44, Percent Change: +0.21%
Revolution Medicines (RVMD) faces an "uphill battle" in pursuing a potential patent infringement claim against Erasca (ERAS), with such legal action seen as risky and unlikely to be effective, RBC Capital Markets said in a Friday research note.The investment firm said Revolution Medicines would likely have to rely on a Doctrine of Equivalents argument to prove infringement, a more difficult path than a literal infringement claim, with the doctrine for chemical compound patents largely lacking legal precedent.The best strategy for Revolution Medicines in the near term would be to try to secure another patent, which, if already pending, may allow the company to pursue a molecule that overlaps more with what Erasca is developing, although this would depend on who filed first.RBC has an outperform rating with a $182 price target.Shares of Revolution Medicines were up 1.3% in Friday trading.Price: $180.44, Change: $+2.27, Percent Change: +1.27%
Revolution Medicines' (RVMD) pancreatic cancer revenue could increase by up to 20% to 40% if positive data emerge from its zoldonrasib and daraxonrasib combination study in metastatic pancreatic ductal adenocarcinoma, UBS Securities said.The company is set to present new safety and efficacy data from its study evaluating zoldonrasib in combination with daraxonrasib in patients with 2L+ KRAS G12D metastatic pancreatic ductal adenocarcinoma, analysts said in a Sunday research note.UBS said it is looking for response rates above 40% for the doublet therapy in the second-line setting as an all-oral regimen.Analysts said they are also looking for updates on the filing of daraxonrasib in 2L PDAC and expect the drug to be approved and launched quickly based on positive commentary from the Food and Drug Administration.UBS has a buy rating on the stock and a $175 price target.Price: $163.98, Change: $+0.99, Percent Change: +0.61%
Margaret A Horn, Chief Operating Officer, on June 15, 2026, sold 93,575 shares in Revolution Medicines (RVMD) for $14,972,110. Following the Form 4 filing with the SEC, Horn has control over a total of 154,647 common shares of the company, with 154,647 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1628171/000161071726000230/xslF345X05/form4.xml
Revolution Medicines' (RVMD) cancer drug daraxonrasib is likely to keep its lead over emerging competitors, as some investors may be overstating the ability of rival treatments to match its performance, RBC Capital Markets said Tuesday in a report.RBC said its analysis suggests competing drugs are unlikely to show meaningful differences from daraxonrasib, setting a high bar ahead of upcoming data in pancreatic and lung cancer. Additional results in both diseases are expected to "converge on darax's profile," reinforcing its position, the report said.RBC said it would be a buyer of Revolution shares ahead of clinical updates from other companies, arguing that more data should highlight daraxonrasib's advantages and ease concerns about competition.Because daraxonrasib is expected to play a major role in treating pancreatic cancer, a rival drug would need to be clearly better and show a different safety and efficacy profile to take meaningful market share, the report said.RBC raised its price target on Revolution stock to $182 from $165 with a rating of outperform, speculative risk.Price: $155.68, Change: $-8.00, Percent Change: -4.89%
Revolution Medicines' (RVMD) full results from its RASolute-302 trial presented at a medical conference indicate that daraxonrasib is emerging as the "clear winner" for the second line treatment of pancreatic cancer, RBC Capital Markets said in a note Monday.The trial is an "inflection point" in second line pancreatic cancer treatment and for Revolution it "represents a large commercial opportunity," the note said.There is now a "clear near-term regulatory path" as well as optionality to bring the drug into other indications, for a potential opportunity of more than $10 billion, RBC said.The investment firm added that while the competitive landscape is intensifying, Revolution's new data sets a "high bar" and Revolution will likely stay the leader in the space.RBC has an outperform rating on Revolution and a $165 price target.Price: $159.93, Change: $+2.45, Percent Change: +1.56%
Revolution Medicines' (RVMD) phase 3 data for daraxonrasib showed improved overall survival and progression-free survival compared with chemotherapy in previously treated metastatic pancreatic cancer, the company said late Sunday.The phase 3 trial met all primary and key secondary endpoints, with daraxonrasib reducing the risk of death by 60% and increasing median overall survival to 13.2 months from about 6.6 months with chemotherapy, Revolution Medicines said.The once-daily oral therapy was generally well tolerated with a manageable safety profile, the company said.Revolution Medicines said it plans to submit data from the trial as part of its new drug application to the US Food and Drug Administration.Shares of Revolution Medicines were up over 10% in Monday premarket trading.Price: $174.50, Change: $+17.02, Percent Change: +10.81%
Showing 1-20 of 32
